摘要
目的:探讨质子泵抑制剂联合XELOX辅助化疗治疗进展期结肠癌的效果。方法:选取2014年5月-2015年5月本院收治的进展期结肠癌患者80例,采用信封法将其分为对照组与观察组,每组40例。两组均进行手术治疗,对照组术后采用XELOX辅助化疗,观察组术后采用质子泵抑制剂联合XELOX辅助化疗。比较两组不同TNM分期及V-ATPase表达情况的1、3、5年无病生存率(DFS)。结果:观察组与对照组V-ATPase表达阳性率分别为67.5%与62.5%,两组比较差异无统计学意义(P>0.05)。两组中ⅡB期患者1、3、5年DFS比较,差异均无统计学意义(P>0.05)。观察组中Ⅲ期患者1、3年DFS高于对照组(P<0.05),而两组Ⅲ期患者5年DFS比较,差异均无统计学意义(P>0.05)。观察组中V-ATPase表达阳性患者1、3年DFS均高于对照组(P<0.05)。结论:质子泵抑制剂联合XELOX辅助化疗可在一定程度上延长Ⅲ期结肠癌与V-ATPase阳性表达患者的术后无病生存期,提高结肠癌患者疗效,建议在临床上推广应用。
Objective:To investigate the efficacy of proton pump inhibitors combined with XELOX adjuvant chemotherapy in the treatment of advanced colon cancer.Method:A total of 80 patients with advanced colon cancer in our hospital from May 2014 to May 2015 were selected.They were divided into control group and observation group by envelope method,40 cases in each group.Two groups were given surgical treatment,the control group was treated with XELOX adjuvant chemotherapy,and the observation group was treated with proton pump inhibitor combined with XELOX adjuvant chemotherapy.The 1-year,3-year and 5-year disease-free survival rates(DFS)were compared between the two groups in different TNM stages and V-ATPase expression.Result:The positive rate of V-ATPase expression in the observation group and the control group were 67.5%and 62.5%,respectively,and there was no significant difference between two groups(P>0.05).There were no significant differences in 1-year,3-yaer,5-year DFS of stageⅡB patients between the two groups(P>0.05).1-year and 3-year DFS of stageⅢpatients in the observation group were higher than those in the control group(P<0.05),while there was no significant difference in 5-year DFS of stageⅢpatients between the two groups(P>0.05).The 1-yaer and 3-year DFS of patients with positive expression of V-ATPase in the observation group were higher than those in the control group(P<0.05).Conclusion:Proton pump inhibitors combined XELOX adjuvant chemotherapy can prolong the disease-free survival of patients with stageⅢcolon cancer and V-ATPase positive expression to a certain extent,and improve the curative effect of patients with colon cancer.It is suggested to be popularized and applied in clinic.
作者
李日明
廖湘晖
吴丽娟
刘祥东
LI Riming;LIAO Xianghui;WU Lijuan;LIU Xiangdong(People’s Hospital of Suixi County,Suixi 524300,China;不详)
出处
《中国医学创新》
CAS
2021年第6期117-120,共4页
Medical Innovation of China
